Abstract:The Hippo pathway plays a critical role in organ size control in development. Deregulation of the Hippo pathway leads to drastic enlargement of organs due to increased cell proliferation, inhibition of apoptosis, and dedifferentiation of differentiated cells. Interestingly, deregulation of the Hippo pathway also plays a critical role in tumorigenesis. However, precise roles of the Hippo pathway in tumorigenesis are unclear. By generating genetically defined liver tumor-initiating cells (TICs) with Hippo pathway inactivation or YAP activation, we found that the Hippo pathway unexpectedly mediates a crosstalk between TICs and the immune system. Via cytokines induced by YAP, TICs actively recruit M2 macrophages from as early as the single-cell stage. Elimination of TIC-associated macrophages (TICAMs) abolishes tumorigenesis in a manner dependent on the immune system. Furthermore, YAP activation has been observed in TICs induced by pathologically relevant oncogenes in murine livers and in human hepatocellular carcinoma (HCC) precancerous lesions. These results demonstrate for the first time that macrophages play a decisive role in the survival of single TIC in vivo and provide a proof of principle for TIC elimination by targeting YAP or M2 macrophages. Furthermore, we found that YAP induces leukocyte-specific integrin β2 (ITGB2) expression in cancer cells, thereby promoting cell invasion through the endothelium in a manner mimicking leukocytes. Through independent biochemical purification and a functional screen, we further identified PR/SET domain 4 (PRDM4) as a transcription factor interacting with the WW domains of YAP to mediate ITGB2 expression and cell invasion. Consistently, ITGB2 and PRDM4 mRNA levels are significantly increased in metastatic prostate cancer. In addition, PRDM4 contributes to YAP-induced tumorigenesis, possibly via mediating the expression of other YAP target genes. Our results demonstrate that YAP promotes cell invasion by inducing leukocyte-specific integrin expression and identify PRDM4 as a novel transcription factor for YAP targets. Citation Format: Xiaocan Guo, Huan Liu, Xiaolei Cao, Bin Zhao. The Hippo pathway in cancer [abstract]. In: Proceedings of the AACR Special Conference on the Hippo Pathway: Signaling, Cancer, and Beyond; 2019 May 8-11; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(8_Suppl):Abstract nr IA21.

The Hippo pathway as an antitumor target: time to focus on

The Hippo signaling pathway: from multiple signals to the hallmarks of cancers

The Hippo Pathway in Biological Control and Cancer Development

Strategies that regulate Hippo signaling pathway for novel anticancer therapeutics

The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer

The Hippo-YAP Pathway in Organ Size Control and Tumorigenesis: an Updated Version.

Targeting the Hippo Pathway for Anti-cancer Therapies.

Hippo Signaling Pathway in Gliomas

Structural Dissection of Hippo Signaling

Hippo Signaling in the Immune System.

New Horizons in Cancer Progression and Metastasis: Hippo Signaling Pathway

The Hippo Pathway As a Drug Target in Gastric Cancer.

Molecular mechanisms of the mammalian Hippo signaling pathway.

YAP/TAZ for cancer therapy: Opportunities and challenges (Review)

The Hippo-YAP pathway: new connections between regulation of organ size and cancer.

Abstract IA21: the Hippo Pathway in Cancer

Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine

Hippo-Yap Signaling Pathway: A New Paradigm for Cancer Therapy

The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment

Advancements of anticancer agents by targeting the Hippo signalling pathway: biological activity, selectivity, docking analysis, and structure–activity relationship

Research Progresses on the Molecular Structure of the Hippo Signaling Pathway Components.